Hanyu Medical, a high-end cardiac device company, has closed a 500 million yuan Series D round of financing jointly led by Highlight Capital, CPE, Yingke PE.
The round also saw participation from Alan AMC, Everest Capital, Medfine Capital, Orient Securities Capital, TF Capital and Spring Fund.
The funds raised will be used to drive the launch of the company's product Valve Clamp, as well as the continued development of new products.
Founded in December 2016, Hanyu Medical is one of the first companies in China to carry out research, development, production and sales of heart valve interventional medical devices. Currently, the company's core product is Valve Clamp, a mitral valve interventional device for minimally invasive interventional treatment of mitral valve regurgitation disease.
Valve Clamp has full proprietary patent rightsin China and has applied for international PCT patents. In addition, Valve Clamp has completed 12 exploratory human clinical trials in October 2018, with a 100% success rate and 100% efficacy rate with no serious complications.